To Evaluate the Long-term Safety and Efficacy of HSK16149 in Chinese Patients With Peripheral Neuralgia

PHASE3CompletedINTERVENTIONAL
Enrollment

301

Participants

Timeline

Start Date

February 17, 2022

Primary Completion Date

July 30, 2023

Study Completion Date

August 7, 2023

Conditions
Peripheral Neuropathic Pain
Interventions
DRUG

HSK16149 40mg BID

HSK16149 40mg , orally twice a day, treatment period; 52-weeks fixed dose.

Trial Locations (24)

100034

Peking University First Hospital, Beijing

Unknown

The First Affiliated Hospital of Anhui Medical University, Hefei

The Second Affiliated Hospital of Anhui Medical University, Hefei

Beijing Pinggu District Hospital, Beijing

Emergency General Hospital, Beijing

The Three Gorges Hospital Affiliated to Chongqing Medical University, Chongqing

The First Hospital of Lanzhou University, Lanzhou

Zhujiang Hospital of Southern Medical University, Guangzhou

Cangzhou People's Hospital, Cangzhou

The Third Hospital of Hebei Medical University, Shijiangzhuang

Kaifeng Hospital of Traditional Chinese Medicine, Kaifeng

The First Affiliated Hospital of Henan University of Science and Technology, Luoyang

Nanyang First People's Hospital, Nanyang

Wuhan Central Hospital, Wuhan

Nanjing First People's Hospital, Nanjing

Pingxiang People's Hospital, Pingxiang

The First Hospital of Jilin University, Changchun

Baotou Central Hospital, Baotou

Jinan Central Hospital, Jinan

The First Affiliated Hospital of Xi'an Medical University, Xi’an

Yuncheng Central Hospital, Yuncheng

The Second People's Hospital of Yibin, Yibin

Zhejiang Provincial People's Hospital, Hangzhou

Taizhou First People's Hospital, Taizhou

All Listed Sponsors
lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY